Georgia Tomaras
Chief, Division of Surgical Sciences
A. Geller Distinguished Professor for Research in Immunology
Professor in Surgery
Professor in Integrative Immunobiology
Professor in Molecular Genetics and Microbiology
Affiliate, Duke Global Health Institute
Dr. Tomaras' overall research program is to understand the cellular and humoral immune response to HIV-1 infection and vaccination that are involved in protection from HIV-1. The research in the Tomaras laboratory centers around three main projects involving 1) antiviral CD8 T cell responses in HIV-1 infection and post vaccination, 2) mucosal and systemic antibody responses to infection and vaccination in both non-human primates and humans and 3) the ontogeny of neutralizing antibodies in HIV-1 infection. Her laboratory is also within the Duke Human Vaccine Institute.
Projects
-
Improved Global HIV-1 Incidence Assay
United States
Publications
-
Gray GE, Mngadi K, Lavreys L, Nijs S, Gilbert PB, Hural J, et al. Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Infect Dis. 2024 Nov;24(11):1201–12.Lin L, Spreng RL, Seaton KE, Dennison SM, Dahora LC, Schuster DJ, et al. GeM-LR: Discovering predictive biomarkers for small datasets in vaccine studies. PLoS Comput Biol. 2024 Nov;20(11):e1012581.Levy Y, Moog C, Wiedemann A, Launay O, Candotti F, Hardel L, et al. Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06). eClinicalMedicine. 2024 Nov 1;77.Rahman MA, Bissa M, Scinto H, Howe SE, Sarkis S, Ma Z-M, et al. Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific response. Nat Commun. 2024 Oct 22;15(1):9102.
See more publications at Scholars@Duke